Literature DB >> 9249972

In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta.

K Cimanga1, T De Bruyne, L Pieters, A J Vlietinck, C A Turger.   

Abstract

Three different extracts and four alkaloids from the root bark of Cryptolepis sanguinolenta have been assessed in vitro against Plasmodium falciparum D-6 (chloroquine-sensitive strain), K-1, and W-2 (chloroquine-resistant strains). Cryptolepine (1) and its hydrochloride (2), 11-hydroxycryptolepine (3), and neocryptolepine (5) showed a strong antiplasmodial activity against P. falciparum chloroquine-resistant strains. Quindoline (4) was less active. The highest activity was obtained with compound 1. In vivo tests on infected mice showed that cryptolepine (1), when tested as its hydrochloride (2), exhibited a significant chemosuppressive effect against Plasmodium berghei yoelii and Plasmodium berghei, berghei, while 1 had the same effect against P. berghei yoelii only. Compounds 3 and 4 did not show activity in this in vivo test system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249972     DOI: 10.1021/np9605246

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  28 in total

1.  Synergistic anti-malarial action of cryptolepine and artemisinins.

Authors:  Arnold D Forkuo; Charles Ansah; Kwesi M Boadu; Johnson N Boampong; Elvis O Ameyaw; Ben A Gyan; Andrea T Arku; Michael F Ofori
Journal:  Malar J       Date:  2016-02-16       Impact factor: 2.979

2.  The clinical efficacy of cryptolepis sanguinolenta in the treatment of malaria.

Authors:  Michael S Tempesta
Journal:  Ghana Med J       Date:  2010-03

Review 3.  A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine.

Authors:  C Ansah; K B Mensah
Journal:  Ghana Med J       Date:  2013-09

4.  An efficient solvent-free synthesis of 2-(alkylamino)-2-oxo-1-arylethyl-6,12-dioxo-6,12-dihydroindolo[1,2-b]isoquinoline-11-carboxylate derivatives via four-component reaction.

Authors:  Tahmineh Kenarkoohi; Abbas Rahmati
Journal:  Mol Divers       Date:  2019-01-05       Impact factor: 2.943

5.  Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents.

Authors:  Xue Y Zhu; Leroy G Mardenborough; Shouming Li; Abdul Khan; Wang Zhang; Pincheng Fan; Melissa Jacob; Shabana Khan; Larry Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2006-11-01       Impact factor: 3.641

6.  Clinical efficacy of a tea-bag formulation of cryptolepis sanguinolenta root in the treatment of acute uncomplicated falciparum malaria.

Authors:  K A Bugyei; G L Boye; M E Addy
Journal:  Ghana Med J       Date:  2010-03

7.  Expedient one-pot synthesis of indolo[3,2-c]isoquinolines via a base-promoted N-alkylation/tandem cyclization.

Authors:  Huy H Nguyen; James C Fettinger; Makhluf J Haddadin; Mark J Kurth
Journal:  Tetrahedron Lett       Date:  2015-09-30       Impact factor: 2.415

8.  Efficient traceless solid-phase synthesis of 3,4-dihydropyrazino[1,2-b]indazoles and their 6-oxides.

Authors:  Nadezda Pudelová; Viktor Krchnák
Journal:  J Comb Chem       Date:  2009 May-Jun

9.  Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.

Authors:  Yi-Chien Lin; Yi-Fong Chen; Li-Shin Tseng; Yueh-Hsuan Lee; Susan L Morris-Natschke; Sheng-Chu Kuo; Ning-Sun Yang; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Eur J Med Chem       Date:  2016-01-07       Impact factor: 6.514

10.  Synthesis and Evaluation of the Tetracyclic Ring-System of Isocryptolepine and Regioiso-Mers for Antimalarial, Antiproliferative and Antimicrobial Activities.

Authors:  Katja S Håheim; Emil Lindbäck; Kah Ni Tan; Marte Albrigtsen; Ida T Urdal Helgeland; Clémence Lauga; Théodora Matringe; Emily K Kennedy; Jeanette H Andersen; Vicky M Avery; Magne O Sydnes
Journal:  Molecules       Date:  2021-05-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.